ClinicalTrials.gg
CompletedNCT06371326Updated Jan 16, 2026

A Study of ZT002 Injection in Participants With Overweight or Obesity

A Phase 1 interventional study of ZT002 Injection and Placebo in Overweight or Obesity, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2023, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd — 2 open to participants now, 7 under way, 1 of them phase 3. Obesity · Beijing QL Biopharmaceutical Co.,Ltd.

Enrollment
9th of 10
28 · median 77
Started
2023
the only one that year
Phase 1
6 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, this one is the 9th largest by enrollment, is the only one that started in 2023, is one of 6 in phase 1, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, or all of them as a file.
02

Study summary

This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 28 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Males and females aged 18 to 50 years (inclusive, based on age at the time of signing the form);

    2. ≥ 24 kg/m2 and \< 28 kg/m2 with at least one of the following concomitant disease (pre-diabetes [except for type 1 or type 2 diabetes], hypertension, hyperlipidemia, fatty liver, obstructive sleep apnoea syndrome, weight-bearing joint pain, etc., see Appendices I and II) or BMI ≥ 28 kg/m2 and ≤ 40 kg/m2 and with or without concomitant disease;

    3. Weight change of no more than 5% (based on self-report) after 3 months of weight control via diet and exercise alone prior to screening, and the formula for calculating weight change is: (highest weight - lowest weight during 3 months of weight control via diet and exercise alone prior to screening) ∕highest weight*100%;

    4. Female subjects are required to adopt abstinence or 2 effective methods of from 1 month prior to screening to 6 months after the last dose, and male subjects are required to adopt abstinence or 2 effective methods of contraception from the first dose to 3 months after the last dose. For male subjects, the effective methods of contraception are as follows: surgical sterilization (e.g., vasectomy) or proper use of condoms, or the female partners use hormonal contraceptives (e.g., contraceptive pills, patches, implantable or injectable) or intrauterine devices (IUDs) or surgical sterilization; for female subjects, the effective methods of contraception are as follows: surgical sterilization (e.g., tubal ligation) or use of IUDs, or male partners properly use condoms or are surgically sterilized, in addition, the female subjects are allowed to use the NMPA-approved hormonal contraceptives (e.g., contraceptive pills, patches, implantable or injectable);

    5. Subjects who have a good understanding of study objectives, be able to communicate well with the investigator, and be able to understand and comply with the requirements set forth for this study.

Exclusion criteria

Exclusion Criteria:

  • 1. History of specific allergies (asthma, eczema, etc.) or allergic constitution, or history of allergy to two or more drugs and foods, especially to the drug and its or GLP-1-containing drugs;

    2. Previous diagnosis of obesity associated with endocrine disease or single gene mutation, including but not limited to, hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, hypogonadism;

    3. Subjects who have had severe gastrointestinal diseases (e.g., active ulcers) or undergone gastrointestinal surgery (except for appendectomy or cholecystectomy) or have abnormalities of gastric emptying (e.g., pyloric obstruction, gastric paralysis) within 6 months prior to screening or have been taking medications that have a direct effect on gastrointestinal motility for a long term, or who are not suitable for participation in the trial as assessed by the investigator;

    4. Prior history of significant cardiovascular disease, defined as:

    a) History of myocardial infarction, coronary angioplasty or bypass grafting, heart valve disease or heart valve repair, clinically significant arrhythmia requiring treatment, unstable angina pectoris, , or cerebrovascular accident within 6 months prior to screening; b) (NYHA) class III or IV congestive cardiac failure;

    5. Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg;

    6. Laboratory test results at screening meet any of the following criteria (one retest is allowed during the screening period if there is any clear reason, and the investigator should document the reason for retest):

    1. Glycosylated () ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol/L, or two-hour plasma glucose ≥ 11.1 mmol/L on oral glucose tolerance test (OGTT) (at screening, subjects with fasting venous plasma glucose between 6.1 and 6.9 mmol/L need to perform OGTT) (see Appendix I, OGTT Test Method);
    2. Thyroid-stimulating hormone (TSH) > 6.0 mIU/L or \< 0.4 mIU/L;
    3. (ALT) and aspartate aminotransferase (AST) ≥ 3 × or blood total ≥ 2 × ULN;
    4. Fasting triglycerides > 5.65 mmol/L;
    5. Blood amylase or blood lipase ≥ 1.5 × ULN;
    6. Calcitonin ≥ 50 ng/L (pg/mL);
    7. Estimated (eGFR) ≤ 60 mL/min/1.73m2, estimated using CKD-EPI formula (see Appendix 3);
    8. Abnormal 12-lead (ECG): second- or third-degree atrioventricular block, long syndrome or QTcF > 450 ms (males) or > 470 ms (females) (see formula in Appendix 4), left or right bundle branch block, pre-excitation syndrome, or other clinically significant arrhythmia (except for sinus arrhythmia);

      7. Previous history of acute and chronic pancreatitis, history of symptomatic gallbladder disease (except for cholecystectomy), history of pancreatic injury, and other high risk factors for pancreatitis;

      8. Previous personal or family history of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia syndrome (MEN2);

      9. Prior diagnosis of (except for cured basal cell skin cancer or cervix carcinoma in situ);

      10. A past history of hypoglycemia or recurrent symptomatic hypoglycemia (more than twice in 6 months);

      11. Infectious disease (which would affect the subject's ability to participate in the trial as judged by the investigator) within 4 weeks prior to screening;

      12. Use of any prescription, over-the-counter, or Chinese herbal medications within 1 month prior to screening or discontinuation less than 5 drug half-lives (whichever is longer);

      13. Use of any of the following medications or therapies within 3 months prior to screening:

    <!-- -->

    1. Any approved or unapproved weight-loss drugs (e.g., liraglutide, semaglutide, beinaglutide, orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion) or weight-affecting Chinese herbal medications, supplements, meal replacements;
    2. Use of any hypoglycemic medications (e.g., sodium-glucose cotransporter protein 2 inhibitors [SGLT2i] and glucagon-like peptide-1 receptor agonists [GLP-1RA], metformin, alpha-glucosidase inhibitors);
    3. Use of medications that may cause significant weight gain, including systemic therapy; tricyclic antidepressants; antipsychotic or antiepileptic drugs (e.g., clomipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine hydrochloride, clozapine, olanzapine, valproic acid and its derivatives, lithium preparations, thioridazine), for more than 1 week;

      14. Subject who have prior history of bariatric surgery (except for those who have undergone liposuction more than 1 year ago) or who plan to undergo bariatric surgery or use bariatric equipment during the study period;

      15. Subjects who have undergone surgery within 3 months prior to screening, or plan to undergo surgery during the study, and anyone who has undergone surgery that affects drug absorption, distribution, metabolism, or excretion;

      16. Subjects who have participated in other clinical trials and received drug therapies or medical device interventions within 3 months prior to screening;

      17. Subjects who have been vaccinated within 1 month prior to screening or plan to be vaccinated during the trial;

      18. Donation or loss of blood ≥ 400 mL, or blood transfusion within 3 months prior to screening;

      19. Subjects who cannot tolerate blood collection by venipuncture or have a history of fainting during acupuncture and seeing blood;

      20. virus surface antigen (HbsAg) positive, or virus (HCV) antibody positive, or (HIV) antibody or Treponema pallidum antibody (TP-Ab) positive at screening;

      21. A history of alcohol abuse (drinking more than 14 units of alcohol per week [1 unit = 360 mL of beer with 5% alcohol, or 45 mL of spirits with 40% alcohol, or 150 mL of wine with 12% alcohol]) within 3 months prior to screening, subjects who have a positive alcohol breathalyzer test at baseline, or who are unable to abstain from alcohol during the study;

      22. History of drug abuse within 3 months prior to screening or a positive drug abuse screening (urine screen);

      23. Subjects who smoke ≥ 5 cigarettes per day within the 3 months prior to screening or who are unable to abstain from smoking throughout the study;

      24. Significantly active or unstable major depression or other major psychiatric conditions or any history of suicide attempt within 2 years prior to screening;

      25. Pregnant or lactating women;

      26. Have other conditions that, in the judgment of the investigator, make participation in this study inappropriate.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    ZT002 Injection

    Participants will be randomized to receive ZT002 injection in 1of 2 dose cohorts.

    Drug: ZT002 Injection

  • Placebo comparator
    ZT002 Placebo

    Participants will be randomized to receive same volume Placebo in 1 of 2 dose cohorts.

    Drug: Placebo

Interventions

  • Participants will receive ZT002 by subcutaneous (SC) injection.

  • DrugPlacebo

    Participants will receive Placebo by subcutaneous (SC) injection.

07

What researchers measure

Primary outcomes

  1. Safety and tolerability of a multiple escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in MAD Cohorts. Number of participants with treatment-emergent adverse events.

    Time frame: up to 270 days

  2. Safety and tolerability of a multiple escalation dose of ZT002 through the incidence severity of serious adverse events in MAD Cohorts. Number of participants with serious adverse events.

    Time frame: up to 270 days

Secondary outcomes

  1. The Pharmacokinetics (PK) profile of a multiple escalation dose of ZT002 in participants with overweight or obesity.

    Parameter: Maximum observed plasma concentration of ZT002 (Css\_max)

    Time frame: up to 270 days

  2. The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in participants with overweight or obesity.

    Parameter: Area under the drug-time curve from 0 h after dosing to the last quantifiable concentration time point (AUC0-τ,SS)

    Time frame: up to 270 days

  3. The anti-drug antibody (ADA) response through testing serum or plasma of the participants post-dosing.

    Time frame: up to 270 days

08

Study locations

1 site
  • First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Apr 2024, 4 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
Apr 17, 2024
StartActual
Nov 21, 2023
Primary completionActual
Apr 15, 2024
CompletionActual
Oct 17, 2024
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06371326
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Nov 21, 2023
Primary completion
Apr 15, 2024
Completion
Oct 17, 2024
Last update
Jan 16, 2026

Study contacts

Xiaoli Li, Master
principal investigator · The First Affiliated Hospital of Bengbu Medical University
Huan Zhou, PhD
principal investigator · The First Affiliated Hospital of Bengbu Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZT002

Start the discussion